Show summary Hide summary
A diabetes medication already proven to protect the heart and kidneys may also reduce the risk of heart failure in people who carry rare genetic changes linked to cardiomyopathy, a new analysis suggests. The finding, drawn from a large randomized trial and reported in Nature Medicine, raises the prospect of using genetic information to guide early preventive treatment — but experts say more research is needed before changing practice.
What the study looked at
Researchers examined data from the DECLARE‑TIMI 58 trial, which enrolled over 12,000 adults with type 2 diabetes at elevated cardiovascular risk. They searched participants’ genetic data for rare variants associated with inherited forms of cardiomyopathy and compared outcomes for those randomized to the SGLT2 inhibitor dapagliflozin versus placebo.
Hollywood directors avert strike: tentative four-year agreement with studios and streamers
Donovan Mitchell’s postseason slump forces Cavs to weigh trade or rebuild
About 121 trial participants carried one or more of these cardiomyopathy-linked variants. After a median follow-up of roughly 4.2 years, the investigators measured hospitalizations for heart failure and new-onset heart failure among carriers and noncarriers.
Key findings
The analysis reported a substantially larger relative benefit from dapagliflozin among the genetic carriers than among noncarriers. While the drug reduced heart-failure hospitalizations across the full trial population, the magnitude of that reduction was markedly greater in people with the cardiomyopathy-associated variants.
- Population studied: more than 12,000 adults with type 2 diabetes (DECLARE‑TIMI 58)
- Genetic carriers identified: ~121 participants
- Follow-up: median ~4.2 years
- Among carriers without prior heart failure, 12.8% assigned to placebo developed heart failure; no heart-failure events were reported among carriers randomized to dapagliflozin during follow-up
- The relative reduction in heart-failure hospitalization was approximately eightfold greater in carriers than in noncarriers (study-reported comparison)
Why this could matter now
Clinicians already prescribe SGLT2 inhibitors like dapagliflozin to lower heart-failure risk in patients with diabetes, chronic kidney disease or established heart failure. If genetic screening can identify a subgroup that receives disproportionately large benefit from earlier treatment, preventive strategies could shift toward targeted use of these drugs before symptoms appear.
That has practical consequences: earlier intervention might prevent hospitalizations and slow progression of heart dysfunction in people whose risk is driven by inherited changes rather than acquired disease.
Limitations and cautions
Experts emphasize this was a secondary genetic analysis of an existing randomized trial, not a prospective trial designed to test dapagliflozin specifically in genetically defined patients. The number of variant carriers was small, which increases uncertainty and makes the results hypothesis‑generating rather than definitive.
Independent cardiologists who reviewed the work called it intriguing and potentially practice‑influencing in the long term, but urged confirmation in larger, dedicated studies before recommending routine genetic screening solely to guide SGLT2‑inhibitor therapy.
Potential pathway to clinical use
Should future trials confirm these observations, clinicians could incorporate genetic testing into cardiovascular risk assessment for selected patients — especially those with a family history of cardiomyopathy or unexplained cardiac dysfunction. That would allow closer monitoring and earlier pharmacologic prevention.
However, the decision to start any preventive medication must remain individualized. Patients with a personal or family history of heart disease should discuss risks and benefits with their clinician before initiating treatment.
Bottom line: This analysis suggests dapagliflozin may offer particularly strong protection against heart failure for people carrying certain cardiomyopathy-linked genetic variants. The finding opens a pathway toward precision prevention, but it requires confirmation in purpose-built clinical trials before it changes standard care.
